If abortion advocates say abortion drugs are "safe" and that the removal of the in-person dispensing requirement was based on science, then why was it necessary to examine the FDA's 2021 review of mifepristone safety? CLI Director of Policy Research and Lozier Library Zack Sluzala, Ph.D., explains. More: lozierinstitute.org/peer-rev… #mifepristone #abortiondrugs #FDA

Claims that abortion drugs are "safe" are unsubstantiated. The @FDA 2021 review of mifepristone safeguards failed to consider real-world conditions in which abortion drugs are used, reflected potential bias towards pro-abortion groups, and relied on insufficient complications reporting. More: lozierinstitute.org/peer-rev… #mifepristone #abortiondrugs #FDA

As an OB-GYN, @docskop has seen the harms of abortion drugs firsthand. She explains the rationale behind a new peer-reviewed publication that analyzes the FDA's relaxed oversight of abortion drugs. Learn more: lozierinstitute.org/peer-rev… #mifepristone #abortiondrugs #FDA

"[T]here is certainly no reason to acknowledge that the FDA has proven safety. They've done actually the opposite." -@docskop on the FDA's lack of evidence in dropping in-person dispensing for abortion drugs. Learn more: lozierinstitute.org/peer-rev… #mifepristone #abortiondrugs #FDA

The decision to remove the in-person dispensing requirement for mifepristone was based on flawed evidence, incomplete data, and potentially biased input. More: lozierinstitute.org/peer-rev… #mifepristone #abortiondrugs #FDA

Abortion activists claim mifepristone is “safer than Tylenol,” and that the FDA’s approval and relaxed oversight of mifepristone are “grounded in science.” But our new peer-reviewed paper exposes that @FDA's review of mifepristone safeguards did not sufficiently show that removal of the in-person dispensing requirement is safe, and may have even been biased towards pro-abortion groups. Read the paper: lozierinstitute.org/peer-rev… #FDA #abortiondrugs #mifepristone

NEW: A peer-reviewed paper from CLI examines the evidence behind @FDA 2021 safety review of the abortion drug mifepristone, which resulted in the removal of the in-person dispensing requirement. Researchers found that the review was based on limited studies and incomplete data, raising serious questions about whether the FDA adequately evaluated the drug’s real-world risks. More: lozierinstitute.org/peer-rev… #FDA #abortiondrugs #mifepristone

Last week @docskop gave a great presentation on the mental health harms of abortion at the 2026 Catholic Medical Association's National Conference. Research shows that women who have abortions have a 138% greater risk of mental health issues than women who have live births. More: lozierinstitute.org/fact-she… #mentalhealth #abortion

The double standard of mifepristone prescription practices is putting pro-abortion ideology ahead of women’s health and safety. Mifepristone has been proposed as a treatment for conditions beyond abortion, including miscarriage, fibroids, weight loss, and depression. The evidence supporting many of these uses, however, remains limited. Even when mifepristone is used for a non-abortion condition, the standard of care is for a physician to evaluate the patient, confirm the diagnosis, determine whether the medication is appropriate, and provide follow-up care throughout the treatment process. Yet current FDA regulations allow for mifepristone to be prescribed for abortion remotely and delivered through the mail with very little medical oversight. Why would a drug require physician supervision for non-abortion uses, but not when it is used to end a life? We must acknowledge that mifepristone’s primary utilization in the U.S. is to electively end unborn life, increasingly through unsupervised use. More: lozierinstitute.org/uses-for… #Mifepristone #AbortionDrugs